Gene · 369
Papers2,279
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 2,279
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
ARAF mutated langerhans cell histiocytosis developed on the background of ARAF/JAK2 mutated polycythaemia vera: evidence of branching evolution from the same progenitor cell. A case report and literature review. | Ann Hematol | 2026 | 42448959 | PubTator, text mining | PubMed |
| A‑Raf: A serine/threonine protein kinase with important biological functions (Review). | Mol Med Rep | 2026 | 42429158 | PubTator, text mining | PubMed |
| Divergent CRD-dependent mechanisms govern RAS isoform-selective recruitment of CRAF and ARAF. | Protein Sci | 2026 | 42423165 | PubTator, text mining | PubMed |
| ARAF regulates malignant progression of bladder cancer through the p38MAPK pathway. | Open Med (Wars) | 2026 | 42205195 | PubTator, text mining | PubMed |
| Cryo-EM structure and biochemical characterization of a BRAF/CRAF heterodimer: Negative charge in the NtA motif is not required for RAF activation. | bioRxiv | 2026 | 42182431 | PubTator, text mining | PubMed |
| Divergent CRD-Dependent Mechanisms Govern RAS Isoform-Selective Recruitment of CRAF and ARAF. | bioRxiv | 2026 | 42182107 | PubTator, text mining | PubMed |
| Rapid activation of ARF6 after RAF inhibition augments BRAFV600E and promotes therapy resistance. | Oncogene | 2026 | 42050077 | PubTator, text mining | PubMed |
| Multi-omics profiling links enhancer-associated MSH6 downregulation to platinum resistance, prognosis, and immune features in ovarian cancer. | Gene | 2026 | 41911956 | PubTator, text mining | PubMed |
| Solubility based mechanistic profiling of combinatorial drug therapy. | Nat Commun | 2026 | 41882025 | PubTator, text mining | PubMed |
| When Erdheim-Chester Disease Reaches the Pectoral Muscle. | Eur J Case Rep Intern Med | 2026 | 41809960 | PubTator, text mining | PubMed |
| GLUD1 supports ovarian cancer progression by counteracting anoikis via ARAF/MEK/ERK signaling. | NPJ Precis Oncol | 2026 | 41786885 | PubTator, text mining | PubMed |
| Broadening horizons: new links between cilia and heart development and disease. | Front Cardiovasc Med | 2026 | 41783016 | PubTator, text mining | PubMed |
| Beyond the Globe: Molecular Diagnostics of Optic Nerve, Orbital, and Adnexal Neoplasms. | Transl Vis Sci Technol | 2026 | 41769942 | PubTator, text mining | PubMed |
| Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing. | Genes (Basel) | 2026 | 41751593 | PubTator, text mining | PubMed |
| From Latent Manifolds to Targeted Molecular Probes: An Interpretable, Kinome-Scale Generative Machine Learning Framework for Family-Based Kinase Ligand Design. | Biomolecules | 2026 | 41750280 | PubTator, text mining | PubMed |
| Proteome-scale autoantibody profiling in PSC: Associations with clinical phenotypes and evidence for neuroendocrine deregulations. | JHEP Rep | 2026 | 41732172 | PubTator, text mining | PubMed |
| The risk of radiation necrosis from combined radiotherapy and BRAF inhibitor in lung adenocarcinoma brain metastases: a comprehensive review and future perspectives. | Front Oncol | 2026 | 41727651 | PubTator, text mining | PubMed |
| Harnessing Ribonucleoprotein Granule Biology for Cancer Therapy: The Central Role of Protein Modifications. | Research (Wash D C) | 2026 | 41716844 | PubTator, text mining | PubMed |
| Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies. | Nat Commun | 2026 | 41654519 | PubTator, text mining | PubMed |
| RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1. | PLoS One | 2026 | 41650121 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/369/papers